Published in Lancet on October 18, 2007
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
Malaria: progress, perils, and prospects for eradication. J Clin Invest (2008) 6.54
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med (2014) 2.79
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med (2015) 2.18
Advances and challenges in malaria vaccine development. J Clin Invest (2010) 2.03
Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis (2013) 2.00
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One (2008) 1.90
Malaria eradication and elimination: views on how to translate a vision into reality. BMC Med (2015) 1.86
Malaria research in the post-genomic era. Nature (2008) 1.78
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J (2009) 1.72
Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A (2009) 1.72
Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One (2009) 1.68
Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One (2009) 1.66
Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS One (2009) 1.64
Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ (2011) 1.62
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One (2008) 1.56
Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin (2010) 1.50
The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection. PLoS One (2013) 1.49
Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications. PLoS One (2014) 1.44
Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS One (2012) 1.43
Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J Biol Chem (2009) 1.41
Public health challenges and prospects for malaria control and elimination. Nat Med (2013) 1.38
Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J (2011) 1.38
Flipping the paradigm on malaria transmission-blocking vaccines. Trends Parasitol (2008) 1.32
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One (2011) 1.32
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One (2009) 1.31
Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One (2009) 1.26
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One (2011) 1.25
Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One (2011) 1.22
Malaria vaccines and their potential role in the elimination of malaria. Malar J (2008) 1.21
Safety and efficacy of neonatal vaccination. Eur J Immunol (2009) 1.17
The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine (2010) 1.17
Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells. PLoS One (2011) 1.15
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J Clin Invest (2014) 1.14
Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J (2011) 1.11
Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect Immun (2009) 1.11
Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children. Malar J (2011) 1.10
A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med (2014) 1.07
Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine. J Immunol (2012) 1.07
T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One (2011) 1.04
Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum Vaccin (2009) 1.01
Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg (2012) 0.99
The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial. PLoS One (2012) 0.99
Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One (2010) 0.99
Genistein-supplemented diet decreases malaria liver infection in mice and constitutes a potential prophylactic strategy. PLoS One (2008) 0.97
The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models. BMC Med (2015) 0.96
Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region. Malar J (2013) 0.94
Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data. BMC Med (2013) 0.94
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. PLoS One (2010) 0.94
A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect Immun (2009) 0.93
Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine. Infect Immun (2012) 0.92
Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine (2010) 0.90
Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults. PLoS One (2015) 0.88
In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs? PLoS Med (2009) 0.88
Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review. Malar J (2009) 0.88
Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model. PLoS One (2010) 0.87
Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS One (2013) 0.87
Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein. Am J Trop Med Hyg (2011) 0.87
Advances and challenges in malaria vaccine development. Expert Rev Mol Med (2009) 0.86
Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine (2008) 0.85
Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens. PLoS One (2011) 0.85
Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses. Clin Vaccine Immunol (2008) 0.85
The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants. Malar J (2015) 0.85
The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan. PLoS Med (2016) 0.83
Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children. PLoS One (2014) 0.83
P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections. PLoS One (2015) 0.83
Identification of key residues involved in fibril formation by the conserved N-terminal region of Plasmodium falciparum merozoite surface protein 2 (MSP2). Biochimie (2010) 0.83
Estimation of vaccine efficacy in a repeated measures study under heterogeneity of exposure or susceptibility to infection. Philos Trans A Math Phys Eng Sci (2008) 0.83
Antigens for pre-erythrocytic malaria vaccines: building on success. Parasite Immunol (2009) 0.83
Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines. Eukaryot Cell (2008) 0.81
Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PLoS One (2013) 0.81
Malaria vaccine: a future hope to curtail the global malaria burden. Int J Prev Med (2014) 0.79
Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research. Biomed Res Int (2013) 0.78
Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. Proc Natl Acad Sci U S A (2017) 0.77
Investigating preferences for mosquito-control technologies in Mozambique with latent class analysis. Malar J (2011) 0.77
What will a partly protective malaria vaccine mean to mothers in Africa? Lancet (2007) 0.76
Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes. Malar J (2014) 0.76
Approaching the target: the path towards an effective malaria vaccine. Mediterr J Hematol Infect Dis (2012) 0.75
Approaches to malaria vaccine development using the retrospectroscope. Infect Immun (2009) 0.75
From discovery to licensure, the Adjuvant System story. Hum Vaccin Immunother (2016) 0.75
A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum. Malar J (2016) 0.75
The clinical development process for a novel preventive vaccine: An overview. J Postgrad Med (2016) 0.75
Protection against malaria a real possibility. J Clin Invest (2007) 0.75
A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials. BMC Pediatr (2009) 0.75
Response to "Poor control vaccines in two randomised trials of malaria vaccine?". Vaccine (2009) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet (2013) 14.06
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet (2004) 9.24
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis (2009) 6.90
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
Malaria: progress, perils, and prospects for eradication. J Clin Invest (2008) 6.54
Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis (2009) 5.90
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis (2002) 5.43
Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med (2008) 4.35
Cause-specific mortality rates in sub-Saharan Africa and Bangladesh. Bull World Health Organ (2006) 4.12
New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov (2009) 4.00
Mass treatment with single-dose azithromycin for yaws. N Engl J Med (2015) 3.84
Some lessons for the future from the Global Malaria Eradication Programme (1955-1969). PLoS Med (2011) 3.42
A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20
Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis (2006) 3.17
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa. Nat Genet (2012) 2.86
Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis J (2009) 2.83
Health and survival of young children in southern Tanzania. BMC Public Health (2008) 2.83
Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial. Lancet (2012) 2.81
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol (2003) 2.71